Farmakonsuma Launches Hidroten® in the Peruvian Market


In 2023, Farmakonsuma, committed to healthcare, introduces a new product in the cardiometabolic field: Hidroten® (Chlorthalidone), a diuretic for the treatment of high blood pressure. With this addition, Farmakonsuma expands its portfolio, offering various options to care for the hearts of the Peruvian population.

High Blood Pressure

High blood pressure (hypertension) increases the workload on the heart and arteries. If not promptly treated, it can damage blood vessels in the brain, heart, and kidneys, leading to conditions like strokes, heart failure, or kidney failure.

Diuretics are used to treat high blood pressure by helping reduce sodium and fluid in the body that flows through veins and arteries, thus lowering blood pressure.

According to the Demographic and Family Health Survey (ENDES), in Peru:

  • There are 5.5 million people aged 15 and older suffering from high blood pressure (22.1%).
  • One in five Peruvians has hypertension.
  • Only half of the diagnosed patients have access to treatment.

The World Health Organization estimates that there are 1.13 billion people worldwide with hypertension, but only one in five hypertensive individuals have their condition under control.

Farmakonsuma and Its Commitment to Cardiovascular Health

Considering the prevalence of this condition, the lack of diagnosis, and optimal treatment for those who suffer from it, we work responsibly through innovation, addressing market needs, and promoting evidence-based continuous medical education at the highest level.

This education is offered to our healthcare professionals and patients, reinforcing our commitment to society.